Determining the Effective Sample Size of a Parametric Prior
From MaRDI portal
Recommendations
Cites work
- Bayesian Approaches to Randomized Trials
- Bayesian Measures of Model Complexity and Fit
- Bayesian statistical modelling
- Counting degrees of freedom in hierarchical and other richly-parameterised models
- Dose-finding with two agents in phase I oncology trials
- Parameterization and Bayesian Modeling
- Statistical Methods for Eliciting Probability Distributions
Cited in
(64)- Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials
- Web-based statistical tools for the analysis and design of clinical trials that incorporate historical controls
- Control of type I error rates in Bayesian sequential designs
- A phase I-II basket trial design to optimize dose-schedule regimes based on delayed outcomes
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials
- The Wasserstein impact measure (WIM): a practical tool for quantifying prior impact in Bayesian statistics
- Random-effects meta-analysis of phase I dose-finding studies using stochastic process priors
- Assessing the effective sample size for large spatial datasets: a block likelihood approach
- Borrowing strength and borrowing index for Bayesian hierarchical models
- Prior effective sample size in conditionally independent hierarchical models
- Effective sample size for a mixture prior
- Sample size determination using posterior predictive distributions
- Sample Size Calculation for Comparing Two Normal Random Samples Using Equilibrium Priors
- Robust meta‐analytic‐predictive priors in clinical trials with historical control information
- Effective sample size in a dichotomous process with noise
- The effective sample size
- Graphical prior elicitation in univariate models
- Prior Sample Size Extensions for Assessing Prior Impact and Prior-Likelihood Discordance
- Quantification of prior impact in terms of effective current sample size
- Predictively consistent prior effective sample sizes
- Inference and Decision Making for 21st-Century Drug Development and Approval
- Iterated multisource exchangeability models for individualized inference with an application to mobile sensor data
- Elastic priors to dynamically borrow information from historical data in clinical trials
- Rethinking the Effective Sample Size
- Prior effective sample size in phase II clinical trials with mixed binary and continuous responses
- DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses
- Optimality of testing procedures for survival data in the nonproportional hazards setting
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- A Bayesian Singular Value Decomposition Procedure for Missing Data Imputation
- The phoropter method: a stochastic graphical procedure for prior elicitation in univariate data models
- Quantifying observed prior impact
- Bayesian dynamic borrowing of historical information with applications to the analysis of large-scale assessments
- BEAST: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
- Bayesian gamma processes for optimizing condition-based maintenance under uncertainty
- Discussion of: ``Specifying prior distributions in reliability applications: towards new formal rules for informative prior elicitation?
- SAM: self-adapting mixture prior to dynamically borrow information from historical data in clinical trials
- Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomes
- REDOMA: Bayesian random-effects dose-optimization meta-analysis using spike-and-slab priors
- A group-sequential randomized trial design utilizing supplemental trial data
- A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling
- Bayesian leveraging of historical control data for a clinical trial with time-to-event endpoint
- Propensity-score-based meta-analytic predictive prior for incorporating real-world and historical data
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
- Bayesian semiparametric prior for historical control borrowing in clinical trials
- Unit information prior for adaptive information borrowing from multiple historical datasets
- Dose finding studies for therapies with late-onset toxicities: a comparison study of designs
- Dual-criterion approach incorporating historical information to seek accelerated approval with application in time-to-event group sequential trials
- A review of methods for research synthesis
- DEMO: dose exploration, monitoring, and optimization using biological and clinical outcomes
- Augmenting treatment arms with external data through propensity-score weighted power priors: an application in expanded access
- Bayesian methods for the design and interpretation of clinical trials in very rare diseases
- TODO: a triple-outcome double-criterion optimal design for dose monitoring-and-optimization in multi-dose randomized trials
- Predictive probabilities made simple: a fast and accurate method for clinical trial decision-making
- A patient similarity-embedded Bayesian approach to prognostic biomarker inference with application to thoracic cancer immunity
- Bayesian sample size determination for binary regression with a misclassified covariate and no gold standard
- Simulation studies on the estimation of sensitivity and specificity in the absence of a gold standard and with rare positive frequencies
- Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD
- Bayesian noninferiority test for 2 binomial probabilities as the extension of Fisher exact test
- A predictive probability interim design for phase II clinical trials with continuous endpoints
- Discussion on ``LEAP: the latent exchangeability prior for borrowing information from historical data
- Reinforced borrowing framework: leveraging auxiliary data for individualized inference
- A Comparative Analysis of Phase I Dose-Finding Designs Incorporating Pharmacokinetics Information
- On divergence measures leading to Jeffreys and other reference priors
- Bayesian models and decision algorithms for complex early phase clinical trials
This page was built for publication: Determining the Effective Sample Size of a Parametric Prior
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3506509)
